Norwegian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
chemotherapy/infarction
Koblingen er lagret på utklippstavlen
9 resultater
Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase of International Application No. PCT/US2014/027450 filed on Mar. 14, 2014, which claims the benefit of U.S. Provisional Application No. 61/785,478 filed on Mar. 14, 2013, each of which are incorporated herein by reference
Medium-chain length fatty acids and glycerides as nephroprotection agents
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The present invention relates to protection against renal failure progression in chronic kidney diseases. This includes the treatment of kidney diseases associated with nephrectomy, renal fibrosis, glomerular sclerosis, and end-stage renal disease. This also includes
Benzimidazolone derivatives as CB2 receptor ligands
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND OF THE INVENTION
This invention relates to benzimidazolone derivatives. These compounds have selective cannabinoid(CB)2 receptor binding activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the
Sulfonyl benzimidazole derivatives
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND OF THE INVENTION
This invention relates to sulfonyl benzimidazole derivatives. These compounds have selective cannabinoid (CB)2 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives
Human G-protein coupled receptor
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor
Antibodies immunospecific for a novel human G-protein coupled receptor family
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor
Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND OF THE INVENTION
The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl)transferase. The compounds of the
Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The present invention relates to variants (mutants) of recombinant protein C and activated protein C, an enzyme that normally has anti-thrombotic, anti-inflammatory, and anti-apoptotic activities. The recombinant activated protein C mutants of the invention have markedly
Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The present invention relates to variants (mutants) of recombinant protein C and activated protein C, an enzyme that normally has anti-thrombotic, anti-inflammatory, and anti-apoptotic activities. The recombinant activated protein C mutants of the invention have markedly
Den mest komplette databasen med medisinske urter støttet av vitenskap
- Fungerer på 55 språk
- Urtekurer støttet av vitenskap
- Urtegjenkjenning etter bilde
- Interaktivt GPS-kart - merk urter på stedet (kommer snart)
- Les vitenskapelige publikasjoner relatert til søket ditt
- Søk medisinske urter etter deres effekter
- Organiser dine interesser og hold deg oppdatert med nyheter, kliniske studier og patenter
Skriv inn et symptom eller en sykdom og les om urter som kan hjelpe, skriv en urt og se sykdommer og symptomer den brukes mot.
* All informasjon er basert på publisert vitenskapelig forskning
